FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
Homerun Resources Inc. Files for Approval of $3 Million Financing; Updates $6 Million Institutional Financing
